Therapeutics
- Ref-No.Technology
- 01-00987
DMD Gene Therapy Approach
- 01-01015
AAV-based split-dCas9 gene activator system for in vivo reprogramming approaches
- 01-01080
Drug combinations to overcome therapy resistance in cancer
- 01-01085
Expansion of pancreatic progenitors derived from human pluripotent stem cells und GMP-compliant conditions
- 02-00311Cystobactamids – novel antibacterials against gram-negative pathogens
- 02-00315Novel Chelocardin Derivatives – resistance breaking atypical tetracyclines with broad-spectrum antibiotic activity
- 02-00316Innovative Inhibitors of Pseudomonas Pathogenicity
- 02-00332Novel inhibitors of Pseudomonas aeruginosa LecB
- 02-00337Novel labyrinthopeptins as anti-viral agents
- 02-00350Novel Ratjadones as payloads in folate-, peptide-, and antibody-drug conjugates for the treatment of cancer
- 02-00351Increased Availability and Efficacy of Aminoglycosides
- 02-00353
High-throughput Screening for anti-herpesviridae Drugs
- 02-00354Highly active Chlorotonil A Derivatives for the treatment of Malaria
- 02-00368Bivalent LecA Inhibitors Targeting Biofilm Formation of Pseudomonas aeruginosa
- 02-00369
Biodynamers enhance drug delivery
- 02-00373Highly potent small molecules prevent tissue damage following S. aureus infection by inhibiting α-hemolysin
- 02-00376
Overcoming resistance - Innovative broad-spectrum inhibitors of Metallo- β-lactamases
- 02-00378
Overcoming resistance - Novel inhibitors of virulence factor LasB of Pseudomonas aeruginosa
- 02-00385Next-Generation Probiotics
- 02-00386
Inhibitors of aconitate decarboxylase 1 – A novel immuno-therapeutic target
- 02-00387
Novel Darobactin Derivatives - highly active antibacterials against gram-negative bacteria
- 02-00395
Novel derivates of griselimycin and their use as antimycobacterial agents
- 02-00396
Novel lectin-targeting conjugates for treatment or diagnosis of bacterial infections
- 02-00397
Novel vaccine vector platform for safe and effective immunization using a replication-deficient murine cytomegalovirus (MCMV)
- 03-00248
MAS-G-Protein-coupled receptor agonists for the treatment of the metabolic syndrome
- 03-00251
Stable Gene Transfer with Hyperactive Sleeping Beauty Transposase SB100X
- 03-00319
Stimulation of arteriogenesis for the prevention of myocardial infarction
- 03-00352
Repurposing Niclosamide for (neo-)adjuvant cancer therapy
- 03-00363
Small molecule inhibitors of STOML3 promise to treat neuropathic pain
- 03-00367Targeting of Autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer’s and vascular dementia
- 03-00393
Novel TPH inhibitors for the treatment of fibrotic diseases and pulmonary arterial hypertension (PAH)
- 03-00397
Plasma cell-specific antibodies targeting BCMA for the treatment of multiple myeloma and autoimmune diseases
- 03-00399/32-00019
Human satellite cells as cell therapy for the treatment of muscle waisting disorders
- 03-00413
Improved Sleeping Beauty Transposon System for gene therapy: SB100X/pT4
- 03-00417
Novel BCMA-CAR for the treatment of multiple myeloma and non-Hodgkin lymphoma (NHL)
- 03-00430
Selective Inhibitors of Genotoxic Stress Induced IKK/NFκB Pathways for Cancer Therapy
- 03-00446
Novel CAR-T against CXCR5 for treatment of non-Hodgkin lymphoma
- 03-00454
ACE2 Inhibitors for therapy of inflammatory skin diseases and stimulation of pigmentation
- 03-00475
Novel combination of inhibitors of WNT and MACC1 for cancer therapy
- 03-00481
Spacer-nick genome editing of hematopoietic stem and progenitor cells and T cells
- 03-00553
Human TCR constructs for adoptive cell therapy of cancer
- 10-00026Novel Benzothiazinones, potent Tuberculosis antibiotics
- 10-00087Jagaricin – a novel antifungal natural compound
- 10-00115Probiotics for Cancer Treatment
- 11-00057Innovative Nerve Sheath Tumor Therapy
- 11-00060
Novel treatment or prevention of age-related diseases extending lifespan
- 11-00065
Nutritional compositions for treating dysfunction of liver fat metabolism – VAFD
- 14-00020
Anti-inflammatory, LPS-neutralizing and anti-bacterial agent against sepsis and other severe bacterial infections
- 14-00020bSALP peptides are potent broad-spectrum anti-viral agents
- 14-00097
Antimicrobial, endotoxine-neutralizing and anti-inflammatory agent for wound healing and treatment of bacterial skin and soft-tissue infections
- 15-00371
lncRNAs in therapy and diagnosis of disease related angiogenesis
- 15-00394Efficient oncolytic anti-tumor therapy based on adenovirus
- 15-00436MicroRNA-125b-5p – a new treatment option for drug induced Acute Liver Failure
- 15-00446
Liver stem cell generation for therapeutic applications
- 15-00461
The physiological breast-milk proteins S100A8 and S100A9 promote an eubiotic gut state in infants
- 15-00514
LS-COAT – an exceptionally efficient tumor vaccination approach
- 15-00611Engineered Immune Cells to Specifically Eliminate Undesired Immune Responses
- 15-00612TCR-agnostic identification of tumor-specific T cells for cancer diagnostics and therapy
- 15-00694
HLA-DR-specific γδ T-cell receptor to treat proliferative disorders of HLA-DR+ cells
- 18-00050
Lonafarnib inhibits cell entry of Human Respiratory Syncytial Virus (hRSV)
- 21-00019
Microelectrode array with combined optical stimulation
- 21-00027
Ferulic acid derivatives as efficient neuroprotective agent and memory enhancer
- 22-00009Quiescent B Cells for immune suppression in gene therapy
- 22-00017Functional IFN-gamma memory in CD4+ T cells: Method for improved T cell therapy and disease monitoring in autoimmune diseases
- 22-00020Bispecific antibodies for cell-type-specific TNF inhibition
- 23-00046
microRNA Signature Indicates Risk for Cognitive Decline
- 23-00064Treating dementia and other brain disorders with natural glycans
- 23-00065Novel treatment of dementia-associated tauopathies
- 23-00069
NMDAR targeted CAAR-T cell therapy
- 23-00075
HERV inhibitors for use in tauopathies
- 32-00059
T-cell therapy of MYD88L265P-dependent B-cell lymphoma
- 32-00076
Next generation allogeneic CAR-NK cell platform for treatment of malignant diseases
- 32-00082
Reprogramming immune cells to develop allogenic CAR cell-based therapies
- 32-00083
CRISPR-Cas induced immunosuppressant resistance in anti-viral T cell products for clinical application
- 32-00101
High-level recombinant adeno-associated virus production
- 32-00164
The CXCR3alt-CXCL11 chemokine system for therapeutic use in solid cancer
- 42-00040
Otviciclib - a new pan-CDK inhibitor in oncology
- 42-00047
Tyrolian algae extract with anti-inflammatory potential
- 44-00013
Keratinophile photosensitizers for safe and rapid treatment of onychomycosis
- 49-00012
A novel approach for acute leukocyte mobilization from the bone marrow